Definition And Pathogenesis

  • Refers to viral or bacterial infection of middle ear cleft.
  • Middle ear cleft encompasses pneumatic spaces, attic, mastoid antrum, and temporal bone air cells.
  • Viral upper respiratory infections precipitate mucosal edema and ciliary hypoactivity.
  • Edema induces eustachian tube obstruction, initiating profound inflammatory response.
  • Disrupted mucociliary transport allows accumulation of middle ear effusion.
  • Pathogens from nasopharynx ascend and colonize static effusion.
  • Shorter, more horizontal, and compliant eustachian tubes predispose young children to infection.

Epidemiology And Risk Factors

  • Peak incidence occurs during first two years of life.
  • Risk factors include day care attendance, passive smoking, and overcrowding.
  • Bottle feeding in supine position and pacifier use increase risk.
  • Underlying conditions like cleft palate, Down syndrome, and immunodeficiency strongly predispose to infection.

Etiology

Pathogen CategorySpecific OrganismsClinical Significance
Primary BacterialStreptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis.Account for approximately 75 percent of cases.
Secondary BacterialStreptococcus pyogenes, Staphylococcus aureus, Pseudomonas aeruginosa.Staphylococcus aureus and gram-negative organisms occur more frequently in neonates.
Viral PathogensRhinovirus, respiratory syncytial virus, adenovirus.Viruses represent sole pathogen in 15 percent of cases.

Clinical Manifestations And Diagnosis

Symptomatology

  • Characterized by rapid onset of ear pain, fever, and irritability.
  • Young infants display ear pulling, excessive crying, and disturbed sleep.
  • Concurrent upper respiratory tract infection symptoms frequently present.

Otoscopic Findings

  • Moderate to severe bulging of tympanic membrane represents most specific diagnostic sign.
  • Tympanic membrane displays decreased or absent mobility on pneumatic otoscopy.
  • Effusion imparts opaque, white, yellow, or amber discoloration to tympanic membrane.
  • Erythema alone without bulging remains insufficient for diagnosis.

Management Strategies

Analgesia And Observation

  • Prompt pain management utilizing acetaminophen or ibuprofen represents crucial initial step.
  • Watchful waiting represents viable strategy for selected cases to minimize antimicrobial resistance.

Criteria For Initial Antibiotic Therapy Versus Observation

Age GroupDisease SeverityManagement Protocol
Under 6 monthsAll cases.Prescribe antibiotic therapy.
6 months to 2 yearsSevere symptoms or bilateral disease.Prescribe antibiotic therapy.
6 months to 2 yearsUnilateral disease without severe symptoms.Antibiotic therapy or 48-72 hour observation.
Over 2 yearsSevere symptoms.Prescribe antibiotic therapy.
Over 2 yearsNonsevere unilateral or bilateral disease.Antibiotic therapy or 48-72 hour observation.

Severe symptoms defined as toxic appearance, otalgia persisting beyond 48 hours, or temperature exceeding 39°C.

Antimicrobial Selection

  • High-dose amoxicillin (80-90 mg/kg/day) serves as first-line therapy.
  • Target duration spans 10 days for younger children or severe disease.
  • Second-line agents indicated for initial treatment failure within 48-72 hours.
  • Amoxicillin-clavulanate (90 mg/kg/day amoxicillin component) targets beta-lactamase producing organisms.
  • Oral cefdinir, cefpodoxime, or intramuscular ceftriaxone represent effective alternative therapies.

Management Of Recurrent Disease

  • Defined as three distinct episodes within 6 months or four episodes within 12 months.
  • Surgical intervention involving tympanostomy tube insertion significantly reduces subsequent episodes.

Complications

CategorySpecific Complications
ExtracranialAcute coalescent mastoiditis, subperiosteal abscess, facial nerve paralysis, labyrinthitis, tympanic membrane perforation.
IntracranialMeningitis, epidural abscess, subdural empyema, brain abscess, sigmoid sinus thrombosis, otitic hydrocephalus.
Chronic SequelaeTympanosclerosis, tympanic membrane atelectasis, adhesive otitis media, acquired cholesteatoma.

Prevention

  • Universal administration of pneumococcal conjugate and influenza vaccines strictly recommended.
  • Eliminate exposure to environmental tobacco smoke.
  • Promote exclusive breast milk feeding during first 6 months of life.